351 results on '"Köhne, C-H"'
Search Results
2. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial
3. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
4. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
5. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013
6. BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial
7. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure
8. Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group
9. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)
10. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)
11. Dünndarmtumoren
12. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features
13. Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients
14. Kolorektales Karzinom
15. Neo-adjuvant Therapy
16. Gastroenterologie
17. Fluoropyrimidines as Antifolate Drugs
18. Analysis of the p53/BAX pathway: Low BAX expression is a negative prognostic factor in patients with resected liver metastases of colorectal adenocarcinoma
19. Dünndarmtumoren
20. Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group
21. Neue Entwicklungen in der Tumortherapie
22. Drug–drug interactions associated with kinase inhibitors: highlighting a new resource for oncologists and clinical pharmacists
23. How to integrate molecular targeted agents in the continuum of care
24. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations
25. PD-028 Retrospective analysis of impact of Köhne prognostic category and BRAF mutation status on survival in patients with RAS wild-type metastatic colorectal cancer treated with second-line FOLFIRI with/without panitumumab
26. PD-026 Survival outcomes in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) classified by Köhne prognostic category and BRAF mutation status: retrospective analysis of the PRIME study
27. Safety and Toxicity of Amphotericin B in Glucose 5% or Intralipid 20% in Neutropenic Patients with Pneumonia or Fever of Unknown Origin: Randomised Study
28. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015
29. An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients
30. Lebermetastasen beim kolorektalem Karzinom: Vielfältige Therapieoptionen nutzen
31. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: A proposal for standardization of patient characteristic reporting and stratification
32. Neoadjuvante Chemotherapie von kolorektalen Lebermetastasen
33. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial
34. Prinzipien der postoperativen Therapie beim Rektumkrazinom
35. Metastatic breast cancer: are we treating the same patients as in the past?
36. Adjuvante Therapie des Kolonkarzinoms
37. Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation
38. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study
39. Adjuvante Behandlung von Patienten mit Rektumkarzinomen: Postoperative Radio-/Chemotherapie oder alleinige Chemotherapie
40. High-dose etoposide phosphate and G-CSF mobilizes peripheral blood stem cells in patients that previously failed to mobilize
41. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
42. UFT – eine Therapieoption für Patienten mit kolorektalem Karzinom
43. Current stages of adjuvant treatment of colon cancer
44. FOLFOX or FOLFIRI in combination with sequentially administered regorafenib as first- or second-line treatment in patients with colorectal cancer: V641
45. Superior CMR-rates with tolerability-adapted imatinib 800 mg vs. 400 mg vs. 400 mg + IFN in CML: The randomized German CML-Study IV: V633
46. Therapy with imatinib in elderly CML patients (≥65 years): Results of the German CML-Study IV: V632
47. Adjuvant therapy of the colon cancer: V470
48. Selected Abstract The gefitinib Long-Term Survivor (LTS) - a species on its own? Molecular and clinico-pathological characteristics of German Long-Term Survivors treated in the Iressa Expanded Access Program (EAP): V357
49. Optimization of imatinib therapy by combination. Final results of the pilot phase of the randomized German CML Study IV: V279
50. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia: A study of 6,515 cases of AML: V27
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.